Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Larocca

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Sensors (Basel, Switzerland)|June 2, 2021
Field-Portable Microplastic Sensing in Aqueous Environments: A Perspective on Emerging TechniquesMorgan G Blevins, Harry L Allen, Beckett C Colson, et al.
Annals of Internal Medicine|February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus VaccineNadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.
Leukemia|February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaA Larocca, S Bringhen, M T Petrucci, et al.
Science Translational Medicine|December 15, 2017
Durability and correlates of vaccine protection against Zika virus in rhesus monkeysPeter Abbink, Rafael A Larocca, Kittipos Visitsunthorn, et al.
Nature Communications|June 24, 2018
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectorsCésar López-Camacho, Peter Abbink, Rafael A Larocca, et al.
Nature|June 30, 2016
Vaccine protection against Zika virus from BrazilRafael A Larocca, Peter Abbink, Jean Pierre S Peron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2017
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Science (New York, N.Y.)|August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysPeter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Sensors (Basel, Switzerland)|June 2, 2021
Field-Portable Microplastic Sensing in Aqueous Environments: A Perspective on Emerging TechniquesMorgan G Blevins, Harry L Allen, Beckett C Colson, et al.
Annals of Internal Medicine|February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus VaccineNadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.
Leukemia|February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaA Larocca, S Bringhen, M T Petrucci, et al.
Science Translational Medicine|December 15, 2017
Durability and correlates of vaccine protection against Zika virus in rhesus monkeysPeter Abbink, Rafael A Larocca, Kittipos Visitsunthorn, et al.
Nature Communications|June 24, 2018
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectorsCésar López-Camacho, Peter Abbink, Rafael A Larocca, et al.
Nature|June 30, 2016
Vaccine protection against Zika virus from BrazilRafael A Larocca, Peter Abbink, Jean Pierre S Peron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2017
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Science (New York, N.Y.)|August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysPeter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
Pageof 9